Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia. Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic). IP: Jaume Alijotas Reig Pathogenic role of cellular microparticles and anti-phospholipid/anti-cofactor antibodies in recurrent implantation failures related to In Vitro Fertilization (IVF). The prevalence of failed IVF is high or very high. Besides problems intrinsic to the technique, we know almost nothing about the possible underlying causes. Anti-phospholipid/anti-cofactor (aPL/aCF) antibodies have been associated to several obstetric complications. Nevertheless, the role that these aPL/aCF antibodies may have in failed IVF is not well defined. With this randomized study we want to understand better the use that these antibodies may have on a clinical daily basis. Along with the microparticles analysis, we could end up by finding several elements that might act as risk markers; in turn, it might even help us to fine-tune the currently used therapeutic approaches. IP: Jaume Alijotas Reig Development of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS/EUROMAP). The so-called obstetric antiphospholipid syndrome seems to have pathogenic, biologic, therapeutic, and evolution features somehow different from the ones observed in those patients who suffer from "classic" antiphospholipid syndrome. Although experience and scientific evidence seem to support this idea, there is a lack of information that allows us to suggest changes in the classification and/or therapeutic criteria. The European Forum on Antiphospholipid Antibody Syndrome has decided to carry on this project and it has chosen the Vall d'Hebron Hospital as the European Coordinating Centre. Many important Spanish and European hospitals will participate in this multicentric study. IP: Jaume Alijotas Reig Proinflammatory cytokines TNF and IL-6 in cellular senescence. A HUVEC aging model. Cells that are chronically exposed to inflammatory signals are more prone to aging than those which are not exposed to such signals. Human vascular endothelial cell (HUVEC) primary cultures activated with TNF-alpha probably increase the expression of ICAM and VCAM, synthesize ROS, and express senescence markers. It is not known what the principal intracellular pathway is (although it is thought that STAT may play a role) and it is unknown if one or more proinflammatory cytokines are needed to activate NF-KB. We are trying to find out the role that IFN-alpha and/or IL-6 and IL-1B may have on the aging inflammatory phenomena and we aim at detecting the intracellular signal pathways (STAT). We are also working on the characterization of the genes involved in these abnormal biologic responses. IP: Jaume Alijotas Reig Pagination Current page 1 Page 2 Page 3 Next page › Last page » Projects Ajuts Grups de Recerca (SGR) 2022 IP: Jaume Alijotas Reig Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Laura Donaire Lancharro, Ariadna Anunciacion Llunell Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00048 Duration: 01/01/2022 - 30/06/2025 Be Sure genetic test to determine dermal filler implant adverse reactions IP: Jaume Alijotas Reig Collaborators: - Funding agency: CERCA (Centres de Recerca de Catalunya) Funding: 10000 Reference: 2020-07-010 Duration: 01/01/2019 - 31/12/2020 Factores angiogénicos durante la gestación y riesgo cardiovascular a medio-largo plazo en las pacientes con preeclampsia. Abordaje clínico y experimental. IP: Jaume Alijotas Reig Collaborators: Manel Mendoza Cobaleda, Josep Perapoch López Funding agency: Instituto de Salud Carlos III Funding: 71995 Reference: PI16/01997 Duration: 01/01/2017 - 31/12/2019 Incorporación del ratio sFlt1/PlGF en el diagnóstico y clasificación de preeclampsia: Ensayo clínico randomizado (EuroPE estudio) IP: Elisa Llurba Olivé Collaborators: Jaume Alijotas Reig, Manel Mendoza Cobaleda Funding agency: Instituto de Salud Carlos III Funding: 111925 Reference: PI16/00375 Duration: 01/01/2017 - 13/06/2017 Pagination Current page 1 Page 2 Page 3 Next page › Last page »
